Lineage Cell Therapeutics Stock Current Valuation
| BTX Stock | ILS 218.20 1.20 0.55% |
Valuation analysis of Lineage Cell Therapeutics helps investors to measure Lineage Cell's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Lineage Cell's price fluctuation is very steady at this time. Calculation of the real value of Lineage Cell Therapeutics is based on 3 months time horizon. Increasing Lineage Cell's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Lineage Cell is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lineage Stock. However, Lineage Cell's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 218.2 | Real 207.17 | Hype 217.0 | Naive 224.74 |
The real value of Lineage Stock, also known as its intrinsic value, is the underlying worth of Lineage Cell Therapeutics Company, which is reflected in its stock price. It is based on Lineage Cell's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Lineage Cell's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Lineage Cell Therapeutics helps investors to forecast how Lineage stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lineage Cell more accurately as focusing exclusively on Lineage Cell's fundamentals will not take into account other important factors: Lineage Cell Therapeutics Company Current Valuation Analysis
Lineage Cell's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Lineage Cell Therapeutics has a Current Valuation of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current valuation for all Israel stocks is 100.0% higher than that of the company.
Lineage Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lineage Cell's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lineage Cell could also be used in its relative valuation, which is a method of valuing Lineage Cell by comparing valuation metrics of similar companies.Lineage Cell is currently under evaluation in current valuation category among its peers.
Lineage Fundamentals
| Price To Book | 1.14 X | |||
| Price To Sales | 39.20 X | |||
| Revenue | 4.99 M | |||
| Gross Profit | 4.69 M | |||
| EBITDA | (37.2 M) | |||
| Net Income | (45.99 M) | |||
| Cash And Equivalents | 27.1 M | |||
| Cash Per Share | 0.18 X | |||
| Total Debt | 5.09 M | |||
| Debt To Equity | 3.10 % | |||
| Current Ratio | 3.51 X | |||
| Book Value Per Share | 1.09 X | |||
| Cash Flow From Operations | (30.88 M) | |||
| Number Of Employees | 76 | |||
| Beta | 2.87 | |||
| Market Capitalization | 512.15 M | |||
| Total Asset | 101.66 M | |||
| Z Score | 60.0 | |||
| Net Asset | 101.66 M |
About Lineage Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lineage Cell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lineage Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lineage Cell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Lineage Stock
When determining whether Lineage Cell Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lineage Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lineage Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lineage Cell Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..